The Clinical Pharmacokinetics of Pyrazinamide in HIV-Infected Persons with Tuberculosis

Clinical Infectious Diseases

Volumn 38, Issue 4, 2004, Pages 556-564

  Perlman, David C ^a   Segal, Yoninah ^c   Rosenkranz, Susan ^c   Rainey, Petrie M ^d   Peloquin, Charles A ^e   Remmel, Rory P ^f   Chirgwin, Keith ^b   Salomon, Nadim ^a   Hafner, Richard ^g  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c Children's Oncology Group Statistics and Data Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MALE; PRIORITY JOURNAL; RELIABILITY;

ADULT; AGE DISTRIBUTION; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRAZINAMIDE; TUBERCULOSIS;

EID: 1342280361     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381096     Document Type: Article

References (36)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 282:677-86.
2. Perlman DC, Hanvanich M. Prophylaxis and treatment of HIV-related tuberculosis. AIDS 1997; 11(Suppl A):S173-9.
3. Barnes PF, Lakey DL, Burman WJ. Tuberculosis in patients with HIV infection. Infect Dis Clin N Am 2002; 16:107-26.
4. American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
5. Berning SE, Huitt GA, Iseman M, et al. Malabsorption of antituberculous medications by a patient with AIDS. N Engl J Med 1992; 327: 1817-8.
6. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications. N Engl J Med 1993; 329:1122-3.
7. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995; 332:336-7.
8. Peloquin CA. Pharmacology issues in the treatment of the tuberculosis. Ann NY Acad Sci 2002; 953:57-164.
9. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30:919-25.
10. Choudhri SH, Hawken M, Gathua S, et al. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 1997; 25:104-11.
11. Taylor I, Smith PJ. Does AIDS impair the absorption of antituberculosis agents? Int J Tuberc Lung Dis 1998; 2:670-5.
12. Gordon SM, Horsburgh CR, Peloquin CA, et al. Low serum levels or oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex diseases. J Infect Dis 1993; 168:1559-62.
13. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999; 28:419-29.
14. El Sadr WE, Perlman DC, Matts JP, et al. The evaluation of an intensive intermittent induction regimen and short course duration of treatment for HIV-related pulmonary tuberculosis. Clin Infect Dis 1998; 26:1148-58.
15. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843-7.
16. Centers for Disease Control and Prevention. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51:214-5.
17. Sandman L, Schluger NW, Davidow AL, et al. Risk factors for rifampin-mono-resistant tuberculosis: a case control study. Am J Respir Crit Care Med 1999; 159:468-72.
18. Munsiff SS, Joseph S, Ebrahimzadeh A, et al. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997; 25:1465-7.
19. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1-51.
20. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-83.
21. Remmel RP, Bushman LR, Fletcher CV. Determination of pyrazinamide and pyrazinoic acid in human plasma by HPLC with UV detection. AAPS Pharm Sci 1999; 1:S603.
22. Yeh KC, Kwan KC. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 1978; 6:79-98.
23. Zhu M, Starke J, Burman WJ, et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 2002; 22:686-95.
24. Peloquin C, Jaresko G, Yong CL, Keung A, Bulpitt A, Jelliffe R. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41:2670-9.
25. Peloquin CA, AE Bulpitt, Jaresko GS, Jelliffe RW, James GT, Nix DE. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy 1998; 18:1205-11.
26. Casella G. Refining binomial confidence intervals. Canadian Journal of Statistics 1986; 14:113-29.
27. Blyth DR, Still HA. Binomial confidence intervals. J Amer Statistical Assoc 1997; 78:108-16.
28. Bergman R, Ludbrook J, Spooren WPJM. Different outcomes of the Wilcoxon-Mann-Whitney test from different statistics packages. American Statistician 2000; 54:72-7.
29. Acocella G, Nonis A, Perna G, Patne E, Gialdroni-Grassi G, Grassi C. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide. Am Rev Respir Dis 1988; 138:886-90.
30. Lacroix C, Hoang TP, Nouveau J, et al. Phramacokinetic of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 1989; 36:395-400.
31. Conte JE, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 1999; 43:1329-33.
32. Crowle AJ, Sbarbaro JA, May MH. Inhibition by pyrazinamide of tubercle bacilli within cultured macrophages. Am Rev Respir Dis 1986; 134:1052-5.
33. Carlone NA, Acocella G, Cuffini AM, Forno-Pizzoglio M. Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination. Am Rev Respir Dis 1985; 132:1274-7.
34. Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 1988; 32:1002-4.
35. Mitchison DA, Dickinson JM. Laboratory aspects of intermittent drug therapy. Postgrad Med J 1971; 47:737-41.
36. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167:1341-7.